FAP and neoplasm: In contrast, Kakarla et al. showed that a FAP-CAR, using the MO35-scFv with human CD28 and CD3 derived domains, controlled tumor burden in a systemic lung carcinoma model without toxicity observed 2 days after T cell injection (27).